Description
Levofloxacin Ecolevid Pharmacodynamics
Levofloxacin is a synthetic broad-spectrum antibacterial agent of fluoroquinolones group, containing the left-handed isomer ofloxacin as an active substance.
Levofloxacin blocks DNA-giase, disrupts superspiralization and cross-linking of DNA breaks, inhibits DNA synthesis, causes profound morphological changes in cytoplasm, cell wall and membranes of bacteria.
Levofloxacin acts bactericidally, it is active against a large number of bacterial pathogens both in vitro and in vivo.
Aerobic Gram-positive microorganisms:
Corynebacterium diphtheriae,
Enterococcus spp. (including Enterococcus faecalis),
Listeria monocytogenes,
Staphylococcus spp. (including Staphylococcus coagulazonegative (sensitive to cmethicillin and moderately sensitive to methicillin), Staphylococcus aureus (sensitive to cmethicillin), Staphylococcus epidermidis (sensitive to methicillin),
Group C and G Streptococci,
Streptococcus agalactiae,
Streptococcus pneumoniae (sensitive and penicillin-resistant),
Streptococcus pyogenes,
Streptococcus viridans (penicillin-sensitive and penicillin-resistant),
Aerobic Gram-negative microorganisms:
Acinetobacter spp. (including Acinetobacter baumannii, Actinobacillus actinomycetemcomitans),
Citrobacter freundii,
Eikenella corrodens,
Enterobacter spp. (including Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae),
Escherichia coli,
Gardnerella vaginalis,
Haemophilus ducreyi,
Haemophilus influenzae (ampicillin sensitive and resistant),
Haemophilus parainfluenzae,
Helicobacter pylori,
Klebsiella spp. (including Klebsiella oxytoca, Klebsiella pneumoniae),
Moraxella catarrhalis,
Morganella morganii,
Neisseria gonorrhoeae (producing and not producing penicillinase),
Neisseria meningitidis,
Pasteurella spp. (including Pasteurella canis, Pasteurella dagmatis, Pasteurella multocida), Proteus mirabilis,
Proteus vulgaris,
Providencia spp. (including Providencia rettgeri, Providencia stuartii),
Pseudomonas spp. (including Pseudomonas aeruginosa),
Salmonella spp,
Serratia spp. (including Serratia marcescens).
Anaerobic microorganisms: Bacteroides fragilis, Bifidobacterium spp., Clostridium perfringens, Fusobacterium spp., Peptostreptococcus spp., Propionibacterum spp., Veilonella spp.
Other microorganisms:
Bartonella spp,
Chlamydia pneumoniae,
Chlamydia psittaci,
Chlamydia trachomatis,
Legionella spp. (including Legionella pneumophila),
Mycobacterium spp. (including Mycobacterium leprae, Mycobacterium tuberculosis), Mycoplasma hominis,
Mycoplasma pneumoniae,
Rickettsia spp,
Ureaplasma urealyticum.
Indications
Infectious-inflammatory diseases caused by microorganisms sensitive to the drug:
– Lower respiratory tract (exacerbation of chronic bronchitis, community-acquired pneumonia);
– ENT-organs (including acute maxillary sinusitis);
– urinary tract and kidneys (including acute pyelonephritis);
– Skin and soft tissue (abscesses, furunculosis);
– Chronic bacterial prostatitis;
– intra-abdominal infections;
– drug-resistant forms of tuberculosis – as part of complex therapy.
Contraindications
Hypersensitivity to levofloxacin, other fluoroquinolones or drug components, epilepsy, tendon affection in previous treatment with quinolones, pregnancy, lactation, children and adolescents (under 18 years). Lactose intolerance or lactase deficiency, as well as glucose-galactose malabsorption.
With caution:
Persons of advanced age, in glucose-6-phosphate dehydrogenase deficiency.
Dosage and administration
- Inside, before a meal or between meals, without chewing, with plenty of fluid.
- Acute maxillary sinusitis: 500 mg once daily for 10-14 days;
Community-acquired pneumonia: 500 mg 1-2 times a day, 7-14 days; - Acute exacerbation of chronic bronchitis: 250-500 mg 1 time per day for 7-10 days; Uncomplicated urinary tract infections:
- 250 mg 1 time per day for 3 days; Complicated urinary tract infections (incl. complicated urinary tract infections (including pyelonephritis): 250 mg 1 time per day (if severe, the dose should be increased) for 7-10 days; Chronic bacterial prostatitis
- – 500 mg 1 time per day, treatment course – 28 days; Skin and soft tissue infections: 250-500 mg 1-2 times daily for 7-14 days; Intra-abdominal infection – 500 mg 1 time per day, treatment course 7-14 days (in combination with antibacterials acting on anaerobic microflora);
- Complex therapy of drug-resistant forms of tuberculosis: 500 mg 1-2 times a day, the course of treatment – up to 3 months;
The duration of treatment depends on the type and severity of the disease. - After relief of symptoms of acute inflammation and normalization of temperature it is recommended to continue therapy with levofloxacin for 48-72 hours.
No dose adjustment is required in patients with liver dysfunction.
